Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

サイズ 価格(税別)  
JPY 50796.00
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中Selleckの製品使用例(72)

カスタマーフィードバック(13)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MXTDfZRwfG:6aXOgRZN{[Xl? M{LZSVExKG6P NGX4dYM4OiCq MWLEUXNQ Mnf1VI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NIPPS5ozPDlyMEi3Ny=>
HT-29 NIP0clNEgXSxdH;4bYMhSXO|YYm= NFjkNHgyOCCwTR?= MmXnO|IhcA>? NHHaOZNFVVOR Ml3vVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 MYqyOFkxODh5Mx?=
HT-29 NITCbmxEgXSxdH;4bYMhSXO|YYm= MmPGNVAhdk1? NGn4PFg4OiCq NIHLUWRFVVOR MnPLVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk> MVSyOFkxODh5Mx?=
PC3 MUfLbY5ie2ViQYPzZZk> M3jSU|ExOCCwTR?= MXyxJIg> NXTXSGdmTE2VTx?= MkjvVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= NYHSPFdMOjF7N{i2PFM>
PC3 MkHxT4lv[XOnIFHzd4F6 M3PyflExOCCwTR?= MUOxJIg> M4Swd2ROW09? NYTxdZQxTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MUmyNVk4QDZ6Mx?=
PC3 NFfjVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\tdXoyNjVizszN NFK5dHgyKGh? NHrtdm1FVVOR MkjuTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P M2n6OVIyQTd6Nkiz
HEK293 NWi0ZnluTnWwY4Tpc44hSXO|YYm= MnHHNVAxKG6P MmXQPEBp Mne2SG1UVw>? MYfJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? NVjrXJpsOjF3M{mzNFE>
BT-20 M3y4b2tqdmG|ZTDBd5NigQ>? MmPpNlAh|ryP M2nKVmROW09? MUjEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? M3O4OVIyOzV|NUWx
U937 NGPveItCdnSrYnHjeIVzcWGuIFHzd4F6 NGSzXHo2OCEQvF2= MYW0PEBp Ml;YSG1UVw>? MoL2TY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| MlfyNlEyPDJzME[=
U937 MUfBcpRq[mGldHXybYFtKEG|c3H5 M1[1cFUxKM7:TR?= NXjkeoJVPDhiaB?= MonESG1UVw>? NUjp[nVITG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NILpZXMzOTF2MkGwOi=>
U937 NHruPVhCdnSrYnHjeIVzcWGuIFHzd4F6 M3fmUlUxKM7:TR?= MVK0PEBp NWmwb4I4TE2VTx?= MonySI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> NYPtZZlLOjFzNEKxNFY>
MCF-7 MWXBeZRweGijZ4mgRZN{[Xl? MX2zNEBvVQ>? MWe0JIg> MoXZSG1UVw>? NHXPXY1KdmS3Y3XzJIF2fG:yaHHnfS=> M4DFW|IxODJ6MUO0
U87MG MWfLbY5ie2ViQYPzZZk> M1LtTFEh|ryP MlTLOkBp M1jGN2ROW09? MV;Qc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? MmHMNVk5PDh2MES=
U87MG NV;VOmxnU2mwYYPlJGF{e2G7 NGXsNmcyKM7:TR?= NXjOdHNjPiCq MX3EUXNQ MWPQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= M1\oV|E6QDR6NEC0
U87MG MVTLbY5ie2ViQYPzZZk> MUKxJO69VQ>? MWO2JIg> MX3EUXNQ MVfEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M1X2[VE6QDR6NEC0
U87MG NGq2[3RMcW6jc3WgRZN{[Xl? NVHLbm5nOSEQvF2= M1nPeFYhcA>? MoW0SG1UVw>? NHjVclJFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? NF7jWlMyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb NHnUZYpCfXSxcHjh[5khSXO|YYm= M2jDU|AvOiEQvF2= MonKNlQhcA>? MmfSSG1UVw>? NW\wVmhnUW6mdXPld{BifXSxcHjh[5k> MVixPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 NUfKdXR[SXW2b4DoZYd6KEG|c3H5 NEPBb|UxNjJizszN Mk\sNlQhcA>? NHv4RZJFVVOR M4XMb2lv\HWlZYOgZZV1d3CqYXf5 NVj1dppQOTh|OUG5OFk>
H4 MVTGeY5kfGmxbjDBd5NigQ>? MWWwMlIh|ryP M37EWVI1KGh? MXPEUXNQ M3zZOmlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> MnrnNVgxOjR3OES=
HeLa MWLGeY5kfGmxbjDBd5NigQ>? NVz3V4xWOTByIH7N MXGzOkBp MUPEUXNQ NX20U2M4UW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? Mn3ENVc2PjN|OEW=
HeLa MUfGeY5kfGmxbjDBd5NigQ>? NFn1R4UyODBibl2= M4XDPFM3KGh? NFPnVXJFVVOR MlTnTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v M1nSW|E4PTZ|M{i1
HeLa NGrmWo5HfW6ldHnvckBCe3OjeR?= M{DLVlExOCCwTR?= MYizOkBp MUfEUXNQ M2m3Rmlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NXLLWFlSOTd3NkOzPFU>
SYF M{THR2Z2dmO2aX;uJGF{e2G7 M{TZZ|ExOCCwTR?= M3nubVI1KGh? M1nndWROW09? NFuy[ItKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NF3qOlUyPzV4M{O4OS=>
SYF M4[1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\mUGwyODBibl2= M3exPFI1KGh? NUG2RpJDTE2VTx?= MYnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy| NVz2PZRsOTd3NkOzPFU>
HEK293T Mm\mRY51cX[rcnHsJGF{e2G7 MYCxJI5O M3\MOFQh\A>? M1:5S2ROW09? MkDOTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= NV3VTVBqOTd2OEW1NFE>
HEK293T MlHJRY51cX[rcnHsJGF{e2G7 NYDubWRkOSCwTR?= MmP4OEBl NEj1cIhFVVOR NUjLb5ZlUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0> NIL3UHUyPzR6NUWwNS=>
PBMC NWLGcY4{TnWwY4Tpc44hSXO|YYm= NHzPeYEyKG6P NUWyPJA{OTRiZB?= NIrVXlNFVVOR M1Lw[XJm\HWlZYOgR2NTPSCmZX7zbZR6 MnjJNVc1QDV3MEG=
PBMC MlWySpVv[3Srb36gRZN{[Xl? NV7Fe4RZOSCwTR?= NWnodnNPOTRiZB?= MlrVSG1UVw>? NV3TfpRwTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? NXT0ZZFmOTd2OEW1NFE>
HEK293 cells NYXUe4lPU2mwYYPlJGF{e2G7 NYnqeZBGPTBibl2= NFPJPWg1PSCvaX6= NWK2V4lOTE2VTx?= NEXGT3ZKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P M1jrU|E4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MonvSpVv[3Srb36gRZN{[Xl? MnvINVAxKG6P MWC0JIg> MmXqSG1UVw>? MUfJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> MnTzNVcyOjh{NkK=
Human mixed lymphocyte MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS1JI5O MkXXSG1UVw>? MlvYTWM2OD1zLk[gcm0v MoLRNVYyQDV6NkW=
Lewis rat lymph node cells M1zLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULyPXJTPSEQvF2= MWjEUXNQ NV7jdVAyUUN3ME2yMlYh|ryP NIqyRlgyPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnQNVAhdk1? MljZO|IhcA>? NXvIToVrTE2VTx?= M3n6VGlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= NYDVfXU5OTByMkG5OFg>
MRK-nu-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uwOWlEPTB;MD64OFUheE1? M3PpXnNCVkeHUh?=
OCUB-M NV7wRY9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLSTWM2OD13LkK0JJBO NImzR5pUSU6JRWK=
SF539 NYHk[Yx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\5c2lEPTB;MUGuOkBxVQ>? NYXPTHZtW0GQR1XS
ES4 NFjiNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELsNmNKSzVyPUKxMlUheE1? MVzTRW5ITVJ?
RL95-2 NHjpS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLmUmlKSzVyPUGwO{BxVQ>? MmLrV2FPT0WU
LC-2-ad NX\VNGp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTR{MzDwUS=> NWXiXVhtW0GQR1XS
Daudi NVj1elV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj1WmNKSzVyPUSzOEBxVQ>? MUXTRW5ITVJ?
NTERA-S-cl-D1 M2jVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q3cGlEPTB;NESzJJBO MXvTRW5ITVJ?
OS-RC-2 NYDCVXpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTuN4FKSzVyPU[1NkBxVQ>? MYrTRW5ITVJ?
VA-ES-BJ NY[ydmJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTd{MzDwUS=> MljnV2FPT0WU
GR-ST MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LId2lEPTB;OES2JJBO M2fk[3NCVkeHUh?=
SW872 MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjhN5ozUUN3ME24OFYheE1? Mn3WV2FPT0WU
NOS-1 NYLxe5M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW0dHRxUUN3ME24O|EheE1? MYTTRW5ITVJ?
MC116 NEHrNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrWb|BKSzVyPUm4OUBxVQ>? NEfZN2lUSU6JRWK=
NCI-H1355 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{K4emlEPTB;MT6wNUBvVQ>? MoLpV2FPT0WU
RPMI-8226 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ETWM2OD1zLkG5JI5O NHS2NJVUSU6JRWK=
TE-15 NGTrSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHSZ49KSzVyPUGuN|Yhdk1? MortV2FPT0WU
Ramos-2G6-4C10 NEnTU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfiU3FKSzVyPUGuOFYhdk1? MnP4V2FPT0WU
KU812 NWOzUGZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jyW2lEPTB;Mj6wNUBvVQ>? MYnTRW5ITVJ?
EW-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnjTWM2OD1{LkG3JI5O M2\SOHNCVkeHUh?=
KS-1 NI[yOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKzTWM2OD1{LkS1JI5O NFvqOlBUSU6JRWK=
SK-LMS-1 NVHhVXBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvXTWM2OD1{LkS5JI5O M3X3UHNCVkeHUh?=
TGBC1TKB MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\nTWM2OD1{Lk[5JI5O NE\nVo9USU6JRWK=
TE-6 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHPOG5VUUN3ME2yMlc4KG6P NHzYc2VUSU6JRWK=
ETK-1 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHHTWM2OD1{LkiyJI5O NXTCd4N1W0GQR1XS
BE-13 NEmxZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fWfWlEPTB;Mj65PUBvVQ>? M1LxXnNCVkeHUh?=
A3-KAW MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fNNGlEPTB;Mj65PUBvVQ>? M{LzSHNCVkeHUh?=
TE-10 NXXuXGNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLnTWM2OD1|LkOgcm0> MkKyV2FPT0WU
DOHH-2 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTNwM{Wgcm0> NWDpW|VJW0GQR1XS
ES6 M1X3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj0co15UUN3ME2zMlQ{KG6P NY\DSJZoW0GQR1XS
OPM-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzSboFKSzVyPUSuNVUhdk1? MkHjV2FPT0WU
SH-4 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OwUWlEPTB;ND6zOEBvVQ>? MV3TRW5ITVJ?
NB13 M2LoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPDTWM2OD12LkO2JI5O M1Kyb3NCVkeHUh?=
HUTU-80 M2TQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XXeWlEPTB;ND60NkBvVQ>? NYjxTHVYW0GQR1XS
CCRF-CEM M4LvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTvb5ZKSzVyPUSuPVQhdk1? MX7TRW5ITVJ?
TGBC24TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjCOG5KSzVyPUWuOVEhdk1? NVTjT4RtW0GQR1XS
697 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTKXVNKSzVyPU[uNlghdk1? MXvTRW5ITVJ?
J-RT3-T3-5 NF:2VoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LQSWlEPTB;Nj60OkBvVQ>? M2OwVHNCVkeHUh?=
KALS-1 M4rNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTZwNU[gcm0> MUHTRW5ITVJ?
no-10 NH;2UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzTeHdZUUN3ME23MlI6KG6P MnHGV2FPT0WU
SK-NEP-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7xSmIxUUN3ME24Mlc6KG6P M2nIZXNCVkeHUh?=
L-540 NX3qc5gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFyLkSyJI5O MX7TRW5ITVJ?
JiyoyeP-2003 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPUOpNKSzVyPUGwMlk1KG6P MoKxV2FPT0WU
HH MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPGZZJKSzVyPUGxMlM6KG6P M1\LVnNCVkeHUh?=
SR MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnDOJM5UUN3ME2xNU41PSCwTR?= M1fSb3NCVkeHUh?=
QIMR-WIL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfGfXNlUUN3ME2xNU45PSCwTR?= NVO1TlU2W0GQR1XS
A4-Fuk M2fqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGflW5NKSzVyPUGzMlEzKG6P MYDTRW5ITVJ?
CESS MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1iwSGlEPTB;MUOuNVMhdk1? MVLTRW5ITVJ?
KE-37 M4focGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPO[WRKSzVyPUG2MlA4KG6P M3vHWnNCVkeHUh?=
SK-UT-1 M{HmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvrTWM2OD1zNj64NUBvVQ>? NWH1[mlsW0GQR1XS
SIG-M5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF5LkK1JI5O M1HmNXNCVkeHUh?=
HT NVXhXFhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPVNXRVUUN3ME2xO{43KG6P MVvTRW5ITVJ?
DEL NUiyc2V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW5TZZKSzVyPUG3Mlk6KG6P NXG3[WU5W0GQR1XS
SK-PN-DW NU\SfZBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO1TWM2OD1{MD6yN{BvVQ>? M4jWbnNCVkeHUh?=
RPMI-8402 NYC0U41qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTnSY8{UUN3ME2yNU44PyCwTR?= NIXUeFdUSU6JRWK=
RPMI-6666 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n5NmlEPTB;MkSuOFIhdk1? MlT2V2FPT0WU
NCI-H720 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmWyTWM2OD1{NT60NUBvVQ>? MUDTRW5ITVJ?
EW-16 NGezU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnmTWM2OD1{Nj64O{BvVQ>? MnTzV2FPT0WU
BL-70 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ6LkO4JI5O M2PyNHNCVkeHUh?=
SF126 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPsco5KSzVyPUOwMlM5KG6P NUnidoVTW0GQR1XS
BC-1 M2HFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[wTpJKSzVyPUOxMlI3KG6P NFfpeVlUSU6JRWK=
MHH-PREB-1 NFzHXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTN{LkS0JI5O MYTTRW5ITVJ?
A101D MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS0N5FiUUN3ME2zNk43OiCwTR?= M{\VXHNCVkeHUh?=
NMC-G1 NIPH[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN|Lk[3JI5O MXPTRW5ITVJ?
LB1047-RCC MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2xbHlHUUN3ME2zOE43QSCwTR?= Mni4V2FPT0WU
EM-2 NITtR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLqW3RCUUN3ME2zPE42OyCwTR?= MYHTRW5ITVJ?
COLO-684 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPHUXFIUUN3ME2zPU45KG6P NX7YVpdGW0GQR1XS
Becker MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTRzLkC1JI5O MXHTRW5ITVJ?
BL-41 M2nWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTvXWhqUUN3ME20N{43PiCwTR?= M4XTT3NCVkeHUh?=
MDA-MB-134-VI MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\4dWNDUUN3ME20OE4xOiCwTR?= M3;Wc3NCVkeHUh?=
L-363 NInvSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTxTWM2OD12ND63N{BvVQ>? MoTtV2FPT0WU
ECC4 NUfFfXdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDEdmdKSzVyPUS0Mlc5KG6P NUThTIhXW0GQR1XS
A388 NX3YO5dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFznTVBKSzVyPUS0MlgzKG6P M4[1eXNCVkeHUh?=
HEL MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr6dGlNUUN3ME20PU44QSCwTR?= MnnJV2FPT0WU
RKO NVW4fm43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTVyLkK5JI5O MoTGV2FPT0WU
KINGS-1 M3HuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmflTWM2OD13MT61OUBvVQ>? MlzqV2FPT0WU
EB-3 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W0dWlEPTB;NUKuOlchdk1? NF\SUYhUSU6JRWK=
ARH-77 M2\0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTV{Lkigcm0> MXPTRW5ITVJ?
GCIY MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTV|LkS2JI5O NG\yWJVUSU6JRWK=
NCI-H1304 NG\UfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP3bYFKSzVyPUW3MlIzKG6P MorvV2FPT0WU
KARPAS-299 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvoZnFkUUN3ME22NU45OiCwTR?= M1L3OHNCVkeHUh?=
IA-LM MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInzNZNKSzVyPU[4MlE{KG6P NEPs[pVUSU6JRWK=
GI-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfmbnVKSzVyPUewMlM6KG6P MYLTRW5ITVJ?
TE-11 NVjId49LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37rTWlEPTB;N{euNVchdk1? Ml\0V2FPT0WU
LS-411N M1XzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTd5LkW3JI5O M1Pz[nNCVkeHUh?=
no-11 NHzTTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD6fpZKSzVyPUizMlI1KG6P MUDTRW5ITVJ?
MV-4-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{faXmlEPTB;OEOuO|Mhdk1? MUXTRW5ITVJ?
BV-173 M3;zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULLdJFZUUN3ME24N{46PyCwTR?= Mn;ZV2FPT0WU
CMK MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTh2LkG2JI5O MonnV2FPT0WU
LC4-1 NUGyT4FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTh4LkeyJI5O MlTPV2FPT0WU
COR-L279 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LPZWlEPTB;OEeuNlUhdk1? M{nBb3NCVkeHUh?=
NCI-H209 MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7qVW1SUUN3ME24O{41OSCwTR?= MmT2V2FPT0WU
Raji NG[1c4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTh7LkeyJI5O MWLTRW5ITVJ?
LB996-RCC M4CxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTl|LkSzJI5O MVTTRW5ITVJ?
NCI-H526 MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\UTWM2OD17Mz61PUBvVQ>? MYDTRW5ITVJ?
KGN M1n3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfGWGdKSzVyPUm2MlI6KG6P Mlq2V2FPT0WU
MOLT-4 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7YRYtQUUN3ME25Ok44QSCwTR?= NHfmVmdUSU6JRWK=
PF-382 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDOcINKSzVyPUm2Mlc6KG6P M3LqUXNCVkeHUh?=
BC-3 NITEPXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe1cHBVUUN3ME25PU4yQCCwTR?= NY\wRZRmW0GQR1XS
KARPAS-422 NHHUbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzCZVJKSzVyPUGwNk4xQSCwTR?= MVfTRW5ITVJ?
SBC-1 NWD4OG9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTZTWM2OD1zMEeuO|Uhdk1? MVrTRW5ITVJ?
LC-1F M{O2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFyOD6wOUBvVQ>? NXzqNIZqW0GQR1XS
GB-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\PTWM2OD1zMEmuNFIhdk1? MmnsV2FPT0WU
SNB75 NYXqUmlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Hqb2lEPTB;MUG5MlY6KG6P NEfLVW9USU6JRWK=
BB65-RCC NF3QPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTpTWM2OD1zMUmuPVMhdk1? M3vvSnNCVkeHUh?=
NCI-N87 MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPOTWM2OD1zMkGuPVghdk1? MXfTRW5ITVJ?
IST-MEL1 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF{Mj6zPEBvVQ>? NHnWVm5USU6JRWK=
HOP-62 NEPhPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF{Nj64PUBvVQ>? MXHTRW5ITVJ?
ACN NF21SJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj5TWM2OD1zNE[uO|Uhdk1? M1OxbnNCVkeHUh?=
DMS-114 MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO4OmxLUUN3ME2xOVAvPjdibl2= MmXQV2FPT0WU
MLMA MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHRTWM2OD1zNUmuPFghdk1? MnrxV2FPT0WU
HT-144 M1v3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDFbGVEUUN3ME2xOlUvPDNibl2= M{nrdXNCVkeHUh?=
C2BBe1 NWSzO3BMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX2Xo8yUUN3ME2xOlcvPzZibl2= MUDTRW5ITVJ?
L-428 NHWzRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvPTYJKSzVyPUG3O{44KG6P MonUV2FPT0WU
DU-4475 M360bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3joUmlEPTB;MUi3MlY5KG6P NEHtRWVUSU6JRWK=
CP67-MEL NWj0UHNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjUSVcxUUN3ME2xPVkvOzhibl2= NXLZd4hHW0GQR1XS
MEG-01 NVS5NnloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LZTmlEPTB;MkCxMlk3KG6P NVPHbW1KW0GQR1XS
IST-SL2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPGfWJKSzVyPUKwPE43OyCwTR?= MVrTRW5ITVJ?
ES8 M2mwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ{NT65OEBvVQ>? NV3GPZBKW0GQR1XS
COLO-800 M3L5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nsPWlEPTB;MkO1MlI5KG6P NUPNc4c3W0GQR1XS
MFH-ino NU\LTJNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ|NT64OEBvVQ>? NWjnOFl[W0GQR1XS
OVCAR-4 NHvRN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnEUpBKSzVyPUKzO{4zPCCwTR?= NFLKO|FUSU6JRWK=
PSN1 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD1RmhKSzVyPUK0Nk44OSCwTR?= NHzuTllUSU6JRWK=
EW-12 M{jTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\Qb2lEPTB;MkSzMlEhdk1? MX7TRW5ITVJ?
HCC1599 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK3bHRKSzVyPUK2NU41PyCwTR?= NYfwWHJSW0GQR1XS
SJSA-1 NIPPXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ5MT60OkBvVQ>? MnHlV2FPT0WU
ST486 NVrQW|BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W0NWlEPTB;Mkm2MlE1KG6P MXHTRW5ITVJ?
NOMO-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LMWmlEPTB;M{CwMlIyKG6P MUHTRW5ITVJ?
MN-60 NUjLe3lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELLTY1KSzVyPUOwOU4{OiCwTR?= M1;JNnNCVkeHUh?=
HCC1187 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNyNz6yOUBvVQ>? NX;mUoVoW0GQR1XS
SW982 M2[4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v5fGlEPTB;M{G0Mlc2KG6P NUDadVJUW0GQR1XS
LB647-SCLC NVHoW4RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTN{OD63NUBvVQ>? M4rZWHNCVkeHUh?=
HC-1 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nFTGlEPTB;M{O1MlUhdk1? NXfxPVhSW0GQR1XS
EHEB NVKyXYNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTN|Nz61NkBvVQ>? MnfBV2FPT0WU
TUR NGX4T2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN4Mz65OUBvVQ>? Mlq0V2FPT0WU
LU-139 NFfZVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN5OD6wNkBvVQ>? NUP3WmJnW0GQR1XS
NB1 NEmzO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;QOJNKUUN3ME2zPFQvPDVibl2= M{njPHNCVkeHUh?=
BB30-HNC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:4UWI5UUN3ME2zPFgvOzJibl2= M3vDR3NCVkeHUh?=
HAL-01 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj1SoVKUUN3ME2zPFkvOjZibl2= M3HLe3NCVkeHUh?=
K5 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRzMT6zO{BvVQ>? MWHTRW5ITVJ?
MZ2-MEL NUHYUI8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTRzMz62OEBvVQ>? MXjTRW5ITVJ?
RXF393 NWjTU3FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonuTWM2OD12MU[uOFUhdk1? M37DSHNCVkeHUh?=
NCI-H1648 M{LQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjV[oFKSzVyPUSxO{42OyCwTR?= M{[1N3NCVkeHUh?=
TE-12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XkR2lEPTB;NEO0MlI3KG6P M4DsSnNCVkeHUh?=
EoL-1- NV;MU3RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XWd2lEPTB;NEO3Mlk5KG6P MlTGV2FPT0WU
JAR NHKyWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR|OD62NkBvVQ>? MonHV2FPT0WU
DSH1 M4XrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\0PFY5UUN3ME20OVgvQTFibl2= MXzTRW5ITVJ?
NCI-H187 NX\DTYliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXSyOFdqUUN3ME20OlIvQDFibl2= NHS4WoxUSU6JRWK=
HCE-4 M2nhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\2TWM2OD12N{euOlYhdk1? M3nvTHNCVkeHUh?=
8-MG-BA M4Gwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T1XWlEPTB;NUixMlUzKG6P MlnJV2FPT0WU
KLE MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i2[mlEPTB;NUi1MlIhdk1? MXPTRW5ITVJ?
KNS-42 M33qSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnuXW5PUUN3ME21PFYvQDFibl2= M3LC[XNCVkeHUh?=
MSTO-211H MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D1TmlEPTB;NkC5Mlc1KG6P M1LNTnNCVkeHUh?=
GDM-1 NXfIUXZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3YcZJoUUN3ME22NVQvODlibl2= M1m1WHNCVkeHUh?=
TE-1 NWfTZlFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfCU2hnUUN3ME22OFYvOTJibl2= MVXTRW5ITVJ?
BT-474 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTZ2Nz6wOkBvVQ>? Mn7lV2FPT0WU
KARPAS-45 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTZ2Nz62JI5O M2XnXnNCVkeHUh?=
MOLT-16 NGm0TmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTZ2Nz65N{BvVQ>? MlHCV2FPT0WU
KURAMOCHI M3P2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjRbnRKSzVyPU[1O{42OSCwTR?= MWjTRW5ITVJ?
K-562 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[wVWlEPTB;Nk[5MlUyKG6P MkfZV2FPT0WU
EKVX M1;pW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfUbppKSzVyPU[3Nk44OSCwTR?= MVjTRW5ITVJ?
GAK M{LsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfUTWM2OD14N{WuN{BvVQ>? MXLTRW5ITVJ?
NCI-SNU-5 M37Q[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTZ7MD6wNUBvVQ>? NH7Nb|FUSU6JRWK=
NCI-H2126 NHPGVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K4XmlEPTB;N{K2Mlg4KG6P NWDqbI9QW0GQR1XS
CTV-1 NXXTWFVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e1Z2lEPTB;N{S0Mlkhdk1? NUC1[WRvW0GQR1XS
SW962 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTd2OD60OEBvVQ>? Mk[4V2FPT0WU
MONO-MAC-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInRWVBKSzVyPUe1Ok46OyCwTR?= Mkj4V2FPT0WU
NCI-H748 NIP1dlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTd3OD65PUBvVQ>? MVzTRW5ITVJ?
NCI-H524 NHXpeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C2UmlEPTB;N{iwMlc{KG6P MXXTRW5ITVJ?
LS-123 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\qPGlEPTB;N{m1MlY6KG6P NVq0cWRbW0GQR1XS
NB7 NGrtbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PicmlEPTB;OEG0MlE1KG6P NH3uV4NUSU6JRWK=
LS-1034 NW\KTnJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mwfGlEPTB;OEK4Mlk5KG6P M1joVHNCVkeHUh?=
TE-5 NF6zcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnHc2Y5UUN3ME24PFMvPTZibl2= MWfTRW5ITVJ?
A704 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvGfnFHUUN3ME24PVkvOTVibl2= MVLTRW5ITVJ?
TK10 M2TIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXoS2tmUUN3ME25NVYvODNibl2= NFTm[YdUSU6JRWK=
NCI-H345 M2rpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXnWWxUUUN3ME25OFMvOjJibl2= NI\YRolUSU6JRWK=
CGTH-W-1 M2D6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\KTWM2OD17NEiuNVMhdk1? NVLN[JR2W0GQR1XS
NCI-H510A MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LKVmlEPTB;OUi1MlEzKG6P M4qwfXNCVkeHUh?=
NCI-H1963 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYewOoFPUUN3ME2xMlA{Ojl{IN88US=> NYH4VpFuW0GQR1XS
SCC-3 Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nteGlEPTB;MT6wN|QyPCEQvF2= MWXTRW5ITVJ?
EW-11 Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXXeG84UUN3ME2xMlA5PzR|IN88US=> MUDTRW5ITVJ?
CPC-N MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLCelhKSzVyPUGuNFg5KM7:TR?= NGPDc3RUSU6JRWK=
NCI-H1417 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP5[lE4UUN3ME2xMlEzOjZizszN MXTTRW5ITVJ?
DG-75 NUjLeFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED5fnRKSzVyPUGuNVYzQDVizszN NFjTPXRUSU6JRWK=
HD-MY-Z NEHNU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwMU[0NVYh|ryP MVzTRW5ITVJ?
ATN-1 M{DHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\QZohKSzVyPUGuNlYzODlizszN Mo\5V2FPT0WU
KM-H2 MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwMk[0NFgh|ryP NHTScpFUSU6JRWK=
NCI-H2081 NVi0TXNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmWxTWM2OD1zLkK2OlM4KM7:TR?= NWC0OmFRW0GQR1XS
HL-60 M1vleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDFTWM2OD1zLkK2PVU6KM7:TR?= NYTOU|FbW0GQR1XS
DB Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTWZ5F2UUN3ME2xMlI4OjR{IN88US=> MWrTRW5ITVJ?
NCI-H1522 NFLZUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwMki4PFch|ryP M3fqXHNCVkeHUh?=
AM-38 NV7Qd|RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPBcXhKSzVyPUGuN|A4OiEQvF2= M1fPfnNCVkeHUh?=
NCI-H446 M{\wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwM{KxNlEh|ryP MW\TRW5ITVJ?
SU-DHL-1 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4GyRmlEPTB;MT6zNlgxOSEQvF2= MkTYV2FPT0WU
NH-12 M333dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfQUG14UUN3ME2xMlM3Ozd2IN88US=> MmPVV2FPT0WU
DMS-79 NFf1XplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnXTWM2OD1zLkO2PFY3KM7:TR?= MV\TRW5ITVJ?
NCI-H716 NGDBc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDOTWM2OD1zLkO4PVg3KM7:TR?= M1f0SXNCVkeHUh?=
ML-2 NV71NIFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwNEG1Nlkh|ryP NHXTUJJUSU6JRWK=
NB10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\QTWM2OD1zLkS2OlMzKM7:TR?= NVewOIo3W0GQR1XS
ONS-76 NXjnfmxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTFwNUO1Olkh|ryP M3q4[nNCVkeHUh?=
LOUCY Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XqNGlEPTB;MT61OFY2PyEQvF2= NXPsSphJW0GQR1XS
SCLC-21H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XZOmlEPTB;MT61PFU5OiEQvF2= M{PVd3NCVkeHUh?=
TGW NV3UblM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzVU5JKSzVyPUGuOlM6PzVizszN MoLvV2FPT0WU
LXF-289 M2nHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwN{OyOlgh|ryP NFGxR45USU6JRWK=
BB49-HNC NWH5RVBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LZUWlEPTB;MT63N|U5PiEQvF2= M{\6UHNCVkeHUh?=
NCI-H747 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwN{WzOFYh|ryP NEHXfZRUSU6JRWK=
LU-165 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDHTWM2OD1zLki0PVg3KM7:TR?= MYTTRW5ITVJ?
OMC-1 NGDkU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH2W29KSzVyPUGuPVUxPjZizszN NEnXUlZUSU6JRWK=
RCC10RGB NXHjPXgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH0O2NKSzVyPUGuPVU5OTdizszN NXvaNmhHW0GQR1XS
SW684 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\lXVlKSzVyPUGuPVYxQTlizszN NGfFfYJUSU6JRWK=
TE-8 NHrWbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3SfG4{UUN3ME2yMlA2PTV7IN88US=> MWDTRW5ITVJ?
SK-N-DZ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF73bYlKSzVyPUKuNVMzPzRizszN MorZV2FPT0WU
EVSA-T NEPZeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwMUezNVUh|ryP MXjTRW5ITVJ?
KASUMI-1 NYixUGxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTPTXBKSzVyPUKuNVg5OTVizszN NYLYdGdHW0GQR1XS
NKM-1 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfCTIxKSzVyPUKuNlU1PzJizszN MmXiV2FPT0WU
CAL-148 NFPZZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOxeFhKSzVyPUKuN|M3OTRizszN NFTzSI5USU6JRWK=
NCI-H64 M2HyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPt[WxKSzVyPUKuN|QzOzJizszN NV64XVVtW0GQR1XS
KNS-81-FD MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojyTWM2OD1{LkO2OlIh|ryP M{S2d3NCVkeHUh?=
KM12 NWPs[pd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTzOYtFUUN3ME2yMlQxQDN7IN88US=> MXzTRW5ITVJ?
SW954 M3v4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHEOlM3UUN3ME2yMlQ4Pzd7IN88US=> NWjMbm0{W0GQR1XS
NCI-H1395 M4LER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrxc|VNUUN3ME2yMlUzPjR3IN88US=> NFizPFFUSU6JRWK=
DJM-1 NHfwN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK1fVBKSzVyPUKuOlA3OyEQvF2= NVfSXHJ[W0GQR1XS
COLO-668 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TROmlEPTB;Mj64NlY6PSEQvF2= NV3iR3RyW0GQR1XS
NCI-H1436 NIT4eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK2bG9KSzVyPUKuPFU3OTVizszN NWrnbmpxW0GQR1XS
LB2241-RCC MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnPTWM2OD1{Lki2PFM6KM7:TR?= MWDTRW5ITVJ?
GT3TKB NX7vZWNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfTUXVrUUN3ME2yMlg6ODV3IN88US=> NWXDO5FYW0GQR1XS
COLO-824 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT5PVIxUUN3ME2yMlg6PzZ6IN88US=> M1u3PHNCVkeHUh?=
ES1 NIGyd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TNW2lEPTB;Mj64PVg4QSEQvF2= Mk[2V2FPT0WU
LB771-HNC NF;UcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XKTmlEPTB;Mj65NFk1PiEQvF2= Mkj6V2FPT0WU
GI-ME-N NVLVb3cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfTTWM2OD1|LkCwPVA1KM7:TR?= MmHIV2FPT0WU
NALM-6 NVy0WVBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj2c|dQUUN3ME2zMlAxQTN|IN88US=> NGXBRZJUSU6JRWK=
LU-134-A MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XxfWlEPTB;Mz6wOVQzPSEQvF2= MXnTRW5ITVJ?
DMS-153 MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfMcWxKSzVyPUOuNFU5OjRizszN NYrNZ5VtW0GQR1XS
MZ1-PC NFqye5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:wS2lEPTB;Mz6wPVA4QCEQvF2= NG\Fe4RUSU6JRWK=
NCI-H1155 NFHUd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DTZWlEPTB;Mz6xNVYyKM7:TR?= MWjTRW5ITVJ?
CAS-1 M{Toe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwMUO3NFch|ryP NHq0dI9USU6JRWK=
D-502MG M2PzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrlXnBKSzVyPUOuNVQ{QSEQvF2= MkHNV2FPT0WU
NCI-H2141 NEDISIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEmzUYpKSzVyPUOuNVc1PTJizszN M{LoUHNCVkeHUh?=
NB6 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vIR2lEPTB;Mz6xPFI2QSEQvF2= MoPEV2FPT0WU
NCCIT NXTwcJp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrqTWM2OD1|LkKxPFA6KM7:TR?= MnLCV2FPT0WU
NB69 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni1TWM2OD1|LkOxPFkyKM7:TR?= M{\0XHNCVkeHUh?=
JVM-2 M33Mdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNwM{[0N|Mh|ryP NILoZ25USU6JRWK=
K052 NW\ScYg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTNwM{e5Olgh|ryP MnTTV2FPT0WU
HCC2157 M2HyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNwNUOyNlgh|ryP M1;LfnNCVkeHUh?=
KMOE-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrmW3NKSzVyPUOuOVQzPDJizszN NYT0VpJZW0GQR1XS
SF268 M3nON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL6WGFbUUN3ME2zMlcyPTV2IN88US=> MUXTRW5ITVJ?
CHP-126 NFTVepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jDeWlEPTB;Mz63OlQ2QCEQvF2= MYrTRW5ITVJ?
CP66-MEL NE\PbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\iXWhKSzVyPUOuO|kxQTRizszN MXvTRW5ITVJ?
NCI-H69 NXXnVFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETKSGhKSzVyPUSuNFE6OzZizszN MnnZV2FPT0WU
A253 M1\IXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHTblFKSzVyPUSuNFIyODFizszN NFTLbVlUSU6JRWK=
NB14 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofvTWM2OD12LkGwOFc6KM7:TR?= NHPpdIJUSU6JRWK=
NCI-H1694 NGSzTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH1fVZzUUN3ME20MlE{OTF{IN88US=> NIPheVJUSU6JRWK=
NCI-H2196 NEnEXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLRTWM2OD12LkG3NVY6KM7:TR?= M{mwS3NCVkeHUh?=
TE-9 NWDBbIl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCzTWM2OD12LkG3OVgzKM7:TR?= NFnZZ2JUSU6JRWK=
D-283MED NUTMSVJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\hTWM2OD12LkG4PFQh|ryP M{XkXnNCVkeHUh?=
OCI-AML2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTRwMUm0PFkh|ryP MULTRW5ITVJ?
D-263MG Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHmUJBKSzVyPUSuNlI6PjFizszN Ml;6V2FPT0WU
MPP-89 NELIfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\We2REUUN3ME20MlI4OzB2IN88US=> NGLFTm5USU6JRWK=
LAMA-84 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XuTWlEPTB;ND6zNFQzOSEQvF2= MkezV2FPT0WU
LB373-MEL-D MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfqc|ZiUUN3ME20MlM3Pzh7IN88US=> NVfRPWVzW0GQR1XS
UACC-257 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTRwM{m1N|Qh|ryP Mk[2V2FPT0WU
MC-CAR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GxbWlEPTB;ND60N|k6KM7:TR?= M3TVR3NCVkeHUh?=
COLO-320-HSR NGW2WVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\jZWNKSzVyPUSuOFQ1OjdizszN NHTqdVNUSU6JRWK=
P30-OHK M2rHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTRwNk[1PFEh|ryP M2P5VnNCVkeHUh?=
UACC-812 M2nnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXk[o9HUUN3ME20MlY6OTZzIN88US=> M{LabXNCVkeHUh?=
CTB-1 NGrvdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKwVZJKSzVyPUSuO|E2PTVizszN NWrVOGdSW0GQR1XS
ALL-PO M4S1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnabZpDUUN3ME20Mlg1ODd5IN88US=> M1rKSnNCVkeHUh?=
SK-MEL-2 M4fkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrHTWM2OD12Lki2PVU2KM7:TR?= Ml3JV2FPT0WU
TC-YIK NG\UR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTRwOUe5OFIh|ryP NH;lcYRUSU6JRWK=
NCI-H1882 NFPlOW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPKNpVHUUN3ME21MlAzODBzIN88US=> MYXTRW5ITVJ?
MHH-CALL-2 NXXDTndRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1OySmlEPTB;NT6wOVA1OiEQvF2= MojQV2FPT0WU
U-87-MG NXrkNoE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnpTWM2OD13LkC5OFY3KM7:TR?= NVvhWnJ2W0GQR1XS
NCI-H1092 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTVwMk[1OVUh|ryP NXq0fmNFW0GQR1XS
TE-441-T M2TlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPPd49KSzVyPUWuNlc5OiEQvF2= MVrTRW5ITVJ?
SK-MEL-1 NGnWOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33hbmlEPTB;NT6yPVA1PCEQvF2= NHyxWGFUSU6JRWK=
EW-22 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HGTGlEPTB;NT6yPVQ3PiEQvF2= MlK3V2FPT0WU
MZ7-mel M17mRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTVwNEC2PVEh|ryP MlzaV2FPT0WU
LP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXnXVlDUUN3ME21MlQyOjlzIN88US=> MV3TRW5ITVJ?
NCI-SNU-16 M4rPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPHfFhKSzVyPUWuOlQxPzRizszN M3nhSXNCVkeHUh?=
LU-65 NVHXSo11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES1RnhKSzVyPUWuO|Y{PzNizszN MUjTRW5ITVJ?
CW-2 M{\jRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfETWM2OD13Lki1PVU6KM7:TR?= M4LBdnNCVkeHUh?=
WSU-NHL NEXqZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvwTWM2OD13Lkm1NVc1KM7:TR?= NGq3O5BUSU6JRWK=
IST-MES1 NV;Q[YhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\kc3BKSzVyPUWuPVU1PDNizszN NYn0ToxXW0GQR1XS
U-266 MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTVwOUiyNFIh|ryP NFXLWYdUSU6JRWK=
TALL-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\zTWM2OD14LkG0Olg5KM7:TR?= NGDXWIFUSU6JRWK=
Calu-6 NYHRbZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\TTWM2OD14LkG1N|E3KM7:TR?= MnfLV2FPT0WU
MMAC-SF NIe4eFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX60UXJtUUN3ME22MlE5PTV4IN88US=> MWHTRW5ITVJ?
NCI-H82 NYHYZXljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\NVGlEPTB;Nj6yNFQ5QSEQvF2= MXvTRW5ITVJ?
RS4-11 Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTZwMkW4PVch|ryP NUfSXWxOW0GQR1XS
SNU-C2B NUjSOFlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTZwNEC5Olkh|ryP M3TDWnNCVkeHUh?=
BOKU MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTZwNEe1PVch|ryP M4LofHNCVkeHUh?=
C8166 M4O5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;1[WlEPTB;Nj61OVkyOiEQvF2= NELENodUSU6JRWK=
D-247MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTdwMESzOFch|ryP MVTTRW5ITVJ?
EW-18 M{TaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i2OWlEPTB;Nz6wO|I6OiEQvF2= NX\jRYQ6W0GQR1XS
KG-1 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHL[2VWUUN3ME23MlYzPzN6IN88US=> M1LMWHNCVkeHUh?=
REH NFTmfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXUfWtKSzVyPUeuOlgyODlizszN NX\ZW3hQW0GQR1XS
U-698-M NYj4SnRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTdwOESzNVUh|ryP NIizXWJUSU6JRWK=
KP-N-RT-BM-1 NGPyPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r3WmlEPTB;Nz65N|AzQSEQvF2= NWjVOWhSW0GQR1XS
MS-1 MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTdwOU[wOFEh|ryP MXnTRW5ITVJ?
SNU-C1 M4XreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n2cGlEPTB;Nz65PFE6OiEQvF2= MYjTRW5ITVJ?
SK-MM-2 NXXFeZQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S4XmlEPTB;OD6yOlA3PSEQvF2= MYjTRW5ITVJ?
LAN-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRThwM{CwNFEh|ryP M2SxSHNCVkeHUh?=
NEC8 NXfnXGVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rnNmlEPTB;OD6zNFY6OSEQvF2= NX7BRmRTW0GQR1XS
NCI-H1770 M1HBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nJRmlEPTB;OD6zPFAxOiEQvF2= NGXlTVVUSU6JRWK=
D-336MG NUSzOoNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmwXmdJUUN3ME24MlQxOTF4IN88US=> NHTxVIlUSU6JRWK=
COLO-829 M4\mTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\mXFFyUUN3ME24MlQ5QDd7IN88US=> MWPTRW5ITVJ?
LS-513 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH60[ZBKSzVyPUiuOVk2QTlizszN MoHuV2FPT0WU
YT NFz6dGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljvTWM2OD16Lk[yOFI4KM7:TR?= Mn7DV2FPT0WU
EW-24 NYrKSo5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[wRmlEPTB;OD63OlU1KM7:TR?= NF\ZSW5USU6JRWK=
IST-SL1 NH\MWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPMTWM2OD16Lki2OVQ{KM7:TR?= M{nwcHNCVkeHUh?=
CA46 NH;Edo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXOTWM2OD16Lkm1NFk5KM7:TR?= NFP0R5RUSU6JRWK=
NCI-H1838 Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zNXGlEPTB;OD65PFYxOiEQvF2= MnjGV2FPT0WU
NCI-H719 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTQTWM2OD17LkK1Nlc6KM7:TR?= MnjPV2FPT0WU
HCE-T M{XzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj4emVWUUN3ME25MlMxQDVzIN88US=> M1zqOXNCVkeHUh?=
A498 NIX3c5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7BNGV1UUN3ME25MlM3OTJ2IN88US=> M3z0VHNCVkeHUh?=
LB831-BLC NELoUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXXd5RFUUN3ME25Mlc3PTJzIN88US=> MWDTRW5ITVJ?
SKM-1 M{[wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DSPGlEPTB;OT64OVk3OyEQvF2= MljwV2FPT0WU
THP-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDNPIpKSzVyPUmuPVY6OThizszN NXnYTYxIW0GQR1XS
SHP-77 M4TuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFyLkSwO{DPxE1? NULhdZRqW0GQR1XS
EW-3 NGLJU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjWNVhKSzVyPUGwMlYzQDlizszN NVPzfoY2W0GQR1XS
KY821 M{TrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvPfVNJUUN3ME2xNE44PjNizszN M2TTRXNCVkeHUh?=
NCI-SNU-1 NEHRUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFzLkCyNVch|ryP NUTSVoRLW0GQR1XS
HCC2218 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSySJZrUUN3ME2xNU4{QTh4IN88US=> Ml\wV2FPT0WU
IM-9 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLEdHRKSzVyPUGxMlUyODZizszN MYTTRW5ITVJ?
NCI-H889 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:4TWM2OD1zMT61N|E{KM7:TR?= M{PRSXNCVkeHUh?=
HDLM-2 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\2TWM2OD1zMj60NVU6KM7:TR?= M3TDe3NCVkeHUh?=
LB2518-MEL MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDQO5RKSzVyPUGyMlY5OTVizszN M13qSnNCVkeHUh?=
NCI-H23 M1[wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF|LkK0NlUh|ryP MlrTV2FPT0WU
NB17 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jweWlEPTB;MUOuOFU4QSEQvF2= M33mVHNCVkeHUh?=
NCI-H322M MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF2LkSwOlgh|ryP NWG0T4M5W0GQR1XS
SUP-T1 NX\6dINWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorwTWM2OD1zND60NVMh|ryP NHrLN4FUSU6JRWK=
ES3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF3LkC3NFMh|ryP MlfCV2FPT0WU
ES5 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF3LkC3PFch|ryP NXPYfVVDW0GQR1XS
NCI-H1650 M4W2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX60cldmUUN3ME2xOU41QTd7IN88US=> NEPUOmJUSU6JRWK=
NCI-H226 Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jYb2lEPTB;MUWuPFc3QCEQvF2= M2nXTnNCVkeHUh?=
COR-L88 NYW3XohmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv0TWM2OD1zNj6zNVQh|ryP NIS3[3hUSU6JRWK=
SCC-15 NWLFSWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP3TWM2OD1zNj6zPFY6KM7:TR?= Mn\ZV2FPT0WU
GOTO NFr2UnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF4LkS3PVMh|ryP M4fxZXNCVkeHUh?=
SIMA NEPkfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfoTWM2OD1zNj60PFAzKM7:TR?= M4m0eXNCVkeHUh?=
NCI-H1299 NXLpO2tkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTSTWM2OD1zNz6xOVkyKM7:TR?= NFfyVVVUSU6JRWK=
NCI-H1581 M2XWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF5LkSyNVkh|ryP MkTTV2FPT0WU
MHH-NB-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rJTWlEPTB;MUeuPVY5OyEQvF2= MoTxV2FPT0WU
MFM-223 M1fuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTSTWM2OD1zOD6wOVM5KM7:TR?= MojaV2FPT0WU
ES7 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF6LkW0N|Eh|ryP MYLTRW5ITVJ?
JVM-3 NEXKb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrFR29EUUN3ME2xPE44OTdizszN NUOyZ|EyW0GQR1XS
RL NYS0VpZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLneXBTUUN3ME2yNE4{QDhizszN NIPKRYFUSU6JRWK=
EC-GI-10 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJzLkKwOFEh|ryP MX7TRW5ITVJ?
LNCaP-Clone-FGC NF7UdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWniWFNFUUN3ME2yNU43PzZ6IN88US=> M{PJSXNCVkeHUh?=
IMR-5 NF[0RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W2fGlEPTB;MkGuPFQ6PCEQvF2= MUnTRW5ITVJ?
KP-N-YS NELpS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n0b2lEPTB;MkGuPFc2KM7:TR?= MXLTRW5ITVJ?
Mo-T NYSz[|ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF23c|RKSzVyPUKyMlIyQDVizszN Mn7jV2FPT0WU
NCI-H128 M2fjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonnTWM2OD1{Mz61PFU{KM7:TR?= MXTTRW5ITVJ?
RH-1 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXyPJZGUUN3ME2yN{44QDZ4IN88US=> MoTXV2FPT0WU
NCI-H2171 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfOTWM2OD1{ND6yOFg2KM7:TR?= MWrTRW5ITVJ?
RPMI-8866 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ4Lke0NkDPxE1? M3Pac3NCVkeHUh?=
SK-N-FI NEntcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ5LkO4NVEh|ryP MXjTRW5ITVJ?
LOXIMVI NXzC[JBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LabWlEPTB;MkeuPFA2OSEQvF2= M3OzVXNCVkeHUh?=
P31-FUJ MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTxTWM2OD1|MT61N|c1KM7:TR?= MYnTRW5ITVJ?
KMS-12-PE NIrLfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn22TWM2OD12OT61N|AzKM7:TR?= M3LaN3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
in solvent
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03454724 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. April 1 2019 Not Applicable
NCT03531281 Not yet recruiting Hematopoietic and Lymphoid Cell Neoplasm|Hematopoietic Cell Transplantation Recipient City of Hope Medical Center|National Cancer Institute (NCI) December 30 2018 Phase 1
NCT03298958 Not yet recruiting Bladder Cancer The University of Texas Health Science Center at San Antonio December 1 2018 Phase 3
NCT03433183 Not yet recruiting Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca December 2018 Phase 2
NCT03721614 Not yet recruiting Coronary Artery Disease Meril Life Sciences Pvt. Ltd. December 1 2018 Not Applicable
NCT03203525 Not yet recruiting Liver Cancer M.D. Anderson Cancer Center|NovoCure Ltd. December 2018 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

mTORシグナル伝達経路

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID